Objective: This retrospective chart review evaluated the efficacy of oral transmucosal fentanyl citrate (OTFC) in an outpatient cancer pain center for patients experiencing severe exacerbations of pain that exceed usual breakthrough pain levels.
I n an outpatient cancer pain center, opioid-tolerant patients presenting with severe exacerbations of pain (Visual Numeric Scale [VNS] Ն7 on a 0-10 scale) that exceed patients' usual breakthrough pain levels is a problematic clinical occurrence. 1 Treatment of these patients requires diagnostic evaluation to determine the source or cause of the pain, as well as to begin a treatment regimen to decrease pain intensity and effec-tively manage the pain. Guidelines established by the National Cancer Care Network (NCCN) suggest administering parenteral opioids for the treatment of severe pain exacerbations, otherwise defined as "pain crises." 2 However, a treatment plan utilizing parenteral opioids has a definite time and monetary cost for patients, physicians, and third-party payers in that a series of steps must be followed to monitor a patient's response. Often, an emergency center (EC) visit and possible admission to the hospital is necessitated while the opioid is adjusted, a diagnosis is confirmed, and a new opioid regimen (or dose adjustment) is initiated.
Oral transmucosal fentanyl citrate (OTFC) is a potent formulation of the short-acting opioid fentanyl, which has been approved by the Food and Drug Administration (FDA), for the treatment of breakthrough pain in opioid-tolerant cancer patients. However, it has not been studied specifically to treat outpatient cancer patients in a pain crisis that might have otherwise been given parenteral opioids as discussed above. Recently, we have begun to use OTFC in our clinic for these patients. If effective in this highly distressed subgroup of patients, OTFC may offer a less-expensive, efficacious alternative to an EC visit and parenteral opioids. Thus, a retrospective chart review was undertaken.
MATERIALS AND METHODS
OTFC is administered in our outpatient cancer pain center to opioid-tolerant patients experiencing a severe exacerbation of pain. This is a fairly common clinical occurrence, with an analysis of pharmacy records indicating 39 such patients (out of 1053 clinic visits) over a recent 3-month time period; approximately 4% of all clinic visits.
After IRB approval, those 39 charts were reviewed, with both clinic records and relevant dictations examined to obtain diagnosis, baseline opioid usage, pre-OTFC pain scores (0-10 VNS scale), OTFC dose and quantity (some patients had a repeated dosage), and post-OTFC pain scores (0-10 VNS scale). Whether or not patients were sent to the emergency center and/or admitted to the hospital that day was also documented. Clinic nursing records were also evaluated for any adverse events following OTFC administration (oversedation, nausea and vomiting, or respiratory depression), although no specific monitoring protocol was used in the clinic.
A paired t test was used to determine whether a statistically significant reduction in pain intensity was reported between scores obtained prior to OTFC treatment and after OTFC treatment. Confidence intervals were also reported for the mean difference. For a descriptive summary, means and standard deviations are presented for pain intensity prior to and after OTFC treatment. All analyses were performed using the SPSS for Windows Version 11 program.
RESULTS
The records of 39 patients were reviewed. Mean patient age was 54.6 years (SD = 12). An approximately equal distribution of male and female patients were noted to be opioid tolerant with a mean MEDD of 265.6 mg/day and a standard deviation of 176.6 mg/day. The minimum MEDD was 40 mg/day, while the maximum MEDD was 750 mg/day. The mean pre-OTFC pain score (VNS) was 9.0. The OTFC dose range used was 200-600 µg, with the most commonly used dose being 400 µg (n = 20). Four patients had one repeat dose 30 minutes after their initial OTFC dose because their pain score remained high. Post-OTFC pain intensity scores (VNS) decreased significantly in all cases down to a mean of 3.0.The paired t test revealed that this mean reduction of 6.0 (SD = 1.5) is highly significant (P < 0.001). The 95% confidence interval for pain reduction is between a range of 5.5-6.5. Seven patients went to the EC, and 3 patients were admitted to the hospital on the day of the visit. Most patients had nociceptive pain (n = 26), 8 had mixed nociceptive and neuropathic syndromes, and 5 had pure neuropathic pain. We did not see any difference in analgesia trends among the different pain types, but the sample sizes were too small to allow statistical comparisons. Side effects, including oversedation, nausea, vomiting, or respiratory depression, were not noted in the clinical records, although no specific monitoring protocol was used in the clinic.
CASE REPORT
Patient 1, who came to the outpatient pain center as an urgent referral for severe exacerbation of pain (Ն7), is illustrated as a representative case. The patient is a 44-year-old African-American female with an advanced anaplastic glioma who was recently diagnosed with leptomeningeal metastasis, including a large metastasis located in the conus from L4 down to the S4 level approximately 8 × 2 cm in size. At the time she came to the outpatient center, she was on a pain regimen of hydromorphone 4-12 mg orally every 3 hours, which was not controlling her pain. Her MEDD was 250 mg. A complete medical history was not obtained prior to treatment of the patient's pain due to the patient screaming out in "10 out of 10" pain and clutching at her right lower extremity. Due to the patient's obvious distress and opioid tolerance, a 400-µg OTFC unit was expeditiously administered. The patient stopped screaming within 15 minutes, and the pain decreased to a "9/10" level by 30 minutes post initial dosing.
At that time, the patient was able to verbalize her medical history while receiving a second 400-µg OTFC unit, and it was noted that the patient had evidence of a sub-acute onset of a lumbosacral plexopathy. Thirty minutes after her second dose of OTFC, her pain score decreased to a level of 6 out of 10, and the patient was visibly much more comfortable. She remained alert and awake with stable vital signs throughout her pain crisis episode. After a discussion with the patient's oncologist, the decision was made to admit her to the hospital for parenteral steroids and probable hospice placement.
DISCUSSION
Opioid-tolerant cancer patients regularly present to our pain clinic with severe exacerbations of pain that exceed their usual breakthrough pain level. OTFC has been shown to have good efficacy in the management of breakthrough pain in opioid-tolerant cancer patients. 3 OTFC is approved for use in opioid-tolerant cancer patients, with tolerance defined (per package insert) as patients taking at least 60 mg of morphine equivalents per day. In our case review, we administered OTFC to opioid-tolerant patients taking Ն40 mg of morphine equivalents per day and clinically have seen no adverse effects in this group (slightly lower than the FDA-approved 60 mg/day morphine equivalents). The oral unit provides rapid onset of analgesia by delivering fentanyl citrate, a potent opioid agonist via the transmucosal route, which quickly attains an effective serum concentration. The maximum serum concentration (T max ) mean is attained by 40 minutes at low dose (200 µg) and 20 minutes at the highest dose (1600 µg). 4, 5 OTFC has been shown to safely and reliably treat episodes of breakthrough pain in opioid-tolerant cancer patients, 6 and it has been shown to be more effective than immediate-release oral morphine in the treatment of breakthrough pain with a potency similar to intravenous morphine. 3 The 200-µg dose has demonstrated similar analgesic properties to 2 mg of intravenous morphine, and the 800-µg dose is comparable to 10 mg of intravenous morphine. 7 Further, the effective dose of OTFC is not proportional to a patient's daily opioid consumption. 8 Thus, our dosing strategy is to start with a 200-to 400-µg OTFC unit (rarely 600 µg) and to repeat in 30 minutes if ineffective rather than starting with a higher dose.
In patients whom we have seen on a regular basis, the management of severe exacerbations of pain in opioid-tolerant cancer patients would have included consideration of parenteral opioids. According to the NCCN Guidelines for the management of cancer pain, intravenous opioids may be indicated for severe cancer pain unresponsive to oral opioids. 2 This is usually accomplished in our clinical setting via the EC. For many reasons this is suboptimal. ECs tend to be overcrowded, leading to treatment delays while patients suffer from unrelent-ing pain. In addition, EC visits may consume expensive health care resources that could be allocated elsewhere. Our report indicates that OTFC demonstrates high efficacy and that, by using this medication, many of our patients probably avoided the need for an EC visit or admission to the hospital. Only 7 of our 39 patients went to the EC (with 3 of the 7 admitted) on the day of the severe pain exacerbation. Prior to OTFC, many of these patients would have been sent from clinic to the EC for parenteral opioids. This result has been suggested in other studies where other authors have reported, in abstract form, avoidance of EC visits in a chronic pain population by use of OTFC. 9 As illustrated in our case report, the use of OTFC allows us to evaluate the patients pain problem more accurately while treating their pain. Thus, we can more thoroughly evaluate the patient and rule out oncologic emergencies including spinal cord compression.
In our opinion, OTFC offers a more convenient and equally safe option (versus parenteral opioids) for gaining control of escalating or out of control pain in the opioid-tolerant cancer patient. In spite of our retrospective analysis, we conclude that OTFC is an effective alternative over intravenous opioids to rapidly titrate analgesia in selected opioid-tolerant cancer patients experiencing severe pain. However, a prospective study is needed to confirm the efficacy and side effect profile compared with the standard approach including parenteral opioids in an outpatient or EC clinical setting.
